<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Child Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/32C75711-61FE-40B1-B099-73E64CC6EF27"><gtr:id>32C75711-61FE-40B1-B099-73E64CC6EF27</gtr:id><gtr:firstName>Hubert</gtr:firstName><gtr:otherNames>Baburaj</gtr:otherNames><gtr:surname>Gaspar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B0FFB06E-0C80-4114-9D30-7040F66F445B"><gtr:id>B0FFB06E-0C80-4114-9D30-7040F66F445B</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thrasher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501468"><gtr:id>74C11668-FA3A-4F07-B495-C526471CBDAC</gtr:id><gtr:title>The role of TACI in the molecular pathogenesis of Common Variable immunodeficiency</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501468</gtr:grantReference><gtr:abstractText>Common variable immunodeficiency (CVID) is a condition which affects the immune system and results in an inability to fight infection, problems with autoimmunity and in some cases development of lymphoma. The gene defect in CVID has only recently been identified. The gene, TACI, is abnormal in CVID but we do not as yet understand why TACI defects leads to the development of the disease. We will first check over 400 CVID patients for abnormalities in TACI so that we can understand how frequent these abnormalities are. Next we plan to look at how abnormal TACI protein works and functions when placed in combination with normal TACI proteins. We also plan to create a mouse model where the TACI gene has been made defective in a way similar to the human condition. This will provide us with a living system where we can examine the effects of TACI defects on the immune system. A greater understanding of these TACI defects will allow us to develop ways of treating CVID in the future.</gtr:abstractText><gtr:technicalSummary>Common variable immunodeficiency (CVID) is a primary immunodeficiency characterised by abnormalities of humoral immunity. The molecular basis of CVID is only now being unravelled and arises from mutations in a number of different genes controlling B cell function and homeostasis. Homozygous and heterozygous mutations in the TNF superfamily receptor TACI (transmembrane calcium modulator and cyclophilin ligand) result in approximately 10% of all cases of CVID although the exact frequency of mutations and the molecular mechanisms by which mutations cause disease are unknown. We have already identified novel missense mutations in a cohort of patients and have developed techniques for high throughput analysis of patient samples. In this study we plan to: 1) study a further 200 patients for TACI mutations usng a combination of screening by heteroduplex analysis and direct screening 2) analyse the consequenses of mutant TACI forms by expression in heterologous cell lines and study the binding to putative ligands and downstream signalling changes 3) generate and study mutant murine models which contain heterozygous mutations in TACI and thereby more closely mimic human defects than previous null mutant strains.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>743688</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Collaboration with European groups as part of a EU consortium on antibody deficiency</gtr:description><gtr:id>EA1F0D54-E090-43BC-A075-6A65498B8C7D</gtr:id><gtr:impact>1) Awarding of FP7 grant 2) research work ongoing at present</gtr:impact><gtr:outcomeId>9A763005AAF-1</gtr:outcomeId><gtr:partnerContribution>Collobaration and exchange of information with other groups in Europe working on Antibody deficiency</gtr:partnerContribution><gtr:piContribution>Analysis of immunodeficient mouse models of antibody deficiency namely the murine TACI deficient model</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F5CF67B4-971C-44C5-B82F-EA2ADEA1E854</gtr:id><gtr:impact>Lecturing at a patient awareness day

n/a</gtr:impact><gtr:outcomeId>6B08083224A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>84000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EC FP7 funding</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>870911B7-9435-4FD4-BF9E-9BC95786C52D</gtr:id><gtr:outcomeId>A06BAEB09A20</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>role of TACI in CVID</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>5A02302A-5BCB-4FE3-AA55-4F509024B32D</gtr:id><gtr:impact>The research undertaken showed that mutations in TACI were not wholly contributory to the CVID phenotype and it is likely that TACI acts as a susceptibility factor</gtr:impact><gtr:outcomeId>4FFF2E6BC46</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We created a knock-in mouse model whereby the most common human TACI variant has been replicated in a murine strain. Rather than study a complete TACI knockout, this now allows us to study the effect of a specific mutation</gtr:description><gtr:id>A2C3246F-9A7E-4196-8F16-D5941ECD6FFF</gtr:id><gtr:impact>to be published in 2010</gtr:impact><gtr:outcomeId>7C455DFFC0E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Murine model of TACI defect</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA collected from patients with CVID</gtr:description><gtr:id>F89FCB64-04CE-46F6-BCB4-E7E477BE8E38</gtr:id><gtr:impact>PUBLICATION 18981294</gtr:impact><gtr:outcomeId>74846D8F08C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DNA from patients with CVID</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B06B6DD9-AE6F-471F-A411-EB34AF791AF9</gtr:id><gtr:title>Sequence analysis of TNFRSF13b, encoding TACI, in patients with systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Journal of clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3003b5e29adf85970fd94a9154c272"><gtr:id>1b3003b5e29adf85970fd94a9154c272</gtr:id><gtr:otherNames>Salzer U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0271-9142</gtr:issn><gtr:outcomeId>EA864E3E39F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3548F965-FD00-45D4-BC49-3FC4CCDFC877</gtr:id><gtr:title>Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b6140241cdee7fb8a0c205f76226d7e"><gtr:id>6b6140241cdee7fb8a0c205f76226d7e</gtr:id><gtr:otherNames>Bacchelli C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>0939D4E996B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45514F96-5ED5-4C3F-B91C-04BBAA238B07</gtr:id><gtr:title>The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b6140241cdee7fb8a0c205f76226d7e"><gtr:id>6b6140241cdee7fb8a0c205f76226d7e</gtr:id><gtr:otherNames>Bacchelli C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>UjNSc92ES2m</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE0ACCC4-520F-4833-A19D-CB01E3FB5BCA</gtr:id><gtr:title>Primary immune deficiencies - principles of care.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68771c77476fac9d6bd64989cca47ff2"><gtr:id>68771c77476fac9d6bd64989cca47ff2</gtr:id><gtr:otherNames>Chapel H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>56dca13e692ef0.72778202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>538628CE-A172-4313-896D-3600DC5C34FD</gtr:id><gtr:title>Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3dbeee43516b36933056e1908ddb5e5"><gtr:id>b3dbeee43516b36933056e1908ddb5e5</gtr:id><gtr:otherNames>Pan-Hammarstr?m Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>E807631EBE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67107B37-BB9E-4AD1-AA01-9BD28A1F5B7D</gtr:id><gtr:title>Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3003b5e29adf85970fd94a9154c272"><gtr:id>1b3003b5e29adf85970fd94a9154c272</gtr:id><gtr:otherNames>Salzer U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>9AD07A8CDDA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78ABE52F-5D97-46AE-9A76-DE6F77E92862</gtr:id><gtr:title>Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3de450c1066c5a2997203794d438fbc4"><gtr:id>3de450c1066c5a2997203794d438fbc4</gtr:id><gtr:otherNames>Wehr C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56dca13e48c4e0.23061413</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501468</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>